Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 3
2006 1
2008 2
2009 2
2010 1
2011 4
2012 3
2014 2
2015 5
2016 3
2017 3
2018 4
2019 1
2020 9
2021 7
2022 1
2023 2
2024 5
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, Sharpe AH, Freeman GJ, Germain RN, Nakaya HI, Xue HH, Ahmed R. Im SJ, et al. Among authors: nasti th. Nature. 2016 Sep 15;537(7620):417-421. doi: 10.1038/nature19330. Epub 2016 Aug 2. Nature. 2016. PMID: 27501248 Free PMC article.
Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer.
Eberhardt CS, Kissick HT, Patel MR, Cardenas MA, Prokhnevska N, Obeng RC, Nasti TH, Griffith CC, Im SJ, Wang X, Shin DM, Carrington M, Chen ZG, Sidney J, Sette A, Saba NF, Wieland A, Ahmed R. Eberhardt CS, et al. Among authors: nasti th. Nature. 2021 Sep;597(7875):279-284. doi: 10.1038/s41586-021-03862-z. Epub 2021 Sep 1. Nature. 2021. PMID: 34471285 Free PMC article.
Reversible, tunable epigenetic silencing of TCF1 generates flexibility in the T cell memory decision.
Abadie K, Clark EC, Valanparambil RM, Ukogu O, Yang W, Daza RM, Ng KKH, Fathima J, Wang AL, Lee J, Nasti TH, Bhandoola A, Nourmohammad A, Ahmed R, Shendure J, Cao J, Kueh HY. Abadie K, et al. Among authors: nasti th. Immunity. 2024 Feb 13;57(2):271-286.e13. doi: 10.1016/j.immuni.2023.12.006. Epub 2024 Jan 31. Immunity. 2024. PMID: 38301652 Free PMC article.
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, Behera M, Wu H, McCausland M, Chen Z, Zhang C, Khuri FR, Owonikoko TK, Ahmed R, Ramalingam SS. Kamphorst AO, et al. Among authors: nasti th. Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998. doi: 10.1073/pnas.1705327114. Epub 2017 Apr 26. Proc Natl Acad Sci U S A. 2017. PMID: 28446615 Free PMC article.
Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer.
Im SJ, Obeng RC, Nasti TH, McManus D, Kamphorst AO, Gunisetty S, Prokhnevska N, Carlisle JW, Yu K, Sica GL, Cardozo LE, Gonçalves ANA, Kissick HT, Nakaya HI, Ramalingam SS, Ahmed R. Im SJ, et al. Among authors: nasti th. Proc Natl Acad Sci U S A. 2023 Oct 10;120(41):e2221985120. doi: 10.1073/pnas.2221985120. Epub 2023 Oct 2. Proc Natl Acad Sci U S A. 2023. PMID: 37782797 Free PMC article.
An early precursor CD8+ T cell that adapts to acute or chronic viral infection.
McManus DT, Valanparambil RM, Medina CB, Scharer CD, McGuire DJ, Sobierajska E, Hu Y, Chang DY, Wieland A, Lee J, Nasti TH, Hashimoto M, Ross JL, Prokhnevska N, Cardenas MA, Gill AL, Clark EC, Abadie K, Kumar AJ, Kaye J, Au-Yeung BB, Kueh HY, Kissick HT, Ahmed R. McManus DT, et al. Among authors: nasti th. Nature. 2025 Apr;640(8059):772-781. doi: 10.1038/s41586-024-08562-y. Epub 2025 Jan 8. Nature. 2025. PMID: 39778710
Early generation of a precursor CD8 T cell that can adapt to acute or chronic viral infection.
McManus DT, Valanparambil RM, Medina CB, Hu Y, Scharer CD, Sobierajska E, Chang DY, Wieland A, Lee J, Nasti TH, Hashimoto M, Ross JL, Prokhnevska N, Cardenas MA, Gill AL, Clark EC, Abadie K, Kueh HY, Kaye J, Au-Yeung BB, Kissick HT, Ahmed R. McManus DT, et al. Among authors: nasti th. Res Sq [Preprint]. 2024 Feb 12:rs.3.rs-3922168. doi: 10.21203/rs.3.rs-3922168/v1. Res Sq. 2024. Update in: Nature. 2025 Apr;640(8059):772-781. doi: 10.1038/s41586-024-08562-y. PMID: 38410458 Free PMC article. Updated. Preprint.
Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
Mariniello A, Nasti TH, Chang DY, Hashimoto M, Malik S, McManus DT, Lee J, McGuire DJ, Cardenas MA, Umana P, Nicolini V, Antia R, Saha A, Buchwald Z, Kissick H, Ghorani E, Novello S, Sangiolo D, Scagliotti GV, Ramalingam SS, Ahmed R. Mariniello A, et al. Among authors: nasti th. Clin Cancer Res. 2024 May 1;30(9):1833-1845. doi: 10.1158/1078-0432.CCR-23-1316. Clin Cancer Res. 2024. PMID: 37992307 Free PMC article.
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA.
Khan MK, Nasti TH, Qian JY, Kleber TJ, Switchenko JM, Kaufman JL, Nooka AJ, Dhodapkar MV, Buchwald ZS, Obiekwe D, Lonial S, Ahmed R. Khan MK, et al. Among authors: nasti th. Lancet Haematol. 2024 Jul;11(7):e510-e520. doi: 10.1016/S2352-3026(24)00105-4. Epub 2024 May 23. Lancet Haematol. 2024. PMID: 38797190 Clinical Trial.
51 results